Clinical trials such as the VISION trial have demonstrated the high efficacy of targeted radiopharmaceutical therapies (TRT), such as 177Lu-PSMA-617 radioligand therapy (PRLT) for mCRPC [6], and the ALSYMPCA trial for the radionuclide targeted α-therapy (TAT) with 223Radium-dichloride (223Ra) selectively targeting bone metastases from prostate cancer [7]. This evidence concerns the gene FOLH1 and prostate carcinoma.